"Flagellated" cancer cells propel anti-tumor immunity

OncoImmunology

Volumn 1, Issue 6, 2012, Pages 940-942

  Garaude, Johan ^a   Blander, J Magarian ^b  

^a INSERM   (France)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adaptive immunity; Flagellin; Immunotherapy; Inflammasome; Innate immunity; Nod like receptor; Pattern recognition receptor; T cell response; Toll like receptor; Vaccination

Indexed keywords

CANCER VACCINE; FLAGELLIN; INNATE IMMUNE RECEPTOR AGONIST; INTERLEUKIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DRUG DESIGN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY;

EID: 84885764046     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20305     Document Type: Article

References (10)

1. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Tolllike receptor agonists and antagonists. Nat Med 2007; 13:552-9; PMID:17479101; http://dx.doi.org/10.1038/nm1589.
2. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010; 327:291-5; PMID:20075244; http://dx.doi.org/10.1126/science.1183021.
3. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006; 440:808-12; PMID:16489357; http://dx.doi.org/10.1038/nature04596.
4. Garaude J, Kent A, van Rooijen N, Blander JM. Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses. Sci Transl Med 2012; 4:20; PMID:22323829; http://dx.doi.org/10.1126/scitranslmed.3002868.
5. Watts C, West MA, Zaru R. TLR signalling regulated antigen presentation in dendritic cells. Curr Opin Immunol 2010; 22:124-30; PMID:20083398; http://dx.doi.org/10.1016/j.coi.2009.12.005.
6. Basha G, Omilusik K, Chavez-Steenbock A, Reinicke AT, Lack N, Choi KB, et al. A CD74-dependent MHC class I endolysosomal cross-presentation pathway. Nat Immunol 2012; 13:237-45; PMID:22306692; http://dx.doi.org/10.1038/ni.2225.
7. Kofoed EM, Vance RE. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 2011; 477:592-5; PMID:21874021; http://dx.doi.org/10.1038/nature10394.
8. Hu B, Elinav E, Huber S, Booth CJ, Strowig T, Jin C, et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci USA 2010; 107:21635-40; PMID:21118981; http://dx.doi.org/10.1073/pnas.1016814108.
9. Normand S, Delanoye-Crespin A, Bressenot A, Huot L, Grandjean T, Peyrin-Biroulet L, et al. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc Natl Acad Sci USA 2011; 108:9601-6; PMID:21593405; http://dx.doi.org/10.1073/pnas.1100981108.
10. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8; PMID:19767732; http://dx.doi.org/10.1038/nm.2028.